Immucell (ICCC) Accounts Payables (2010 - 2026)
Immucell's (ICCC) quarterly Accounts Payables came in at $2.3 million in Q4 2025, down 8.05% YoY from $2.5 million in Q4 2024, and down 1.77% on a QoQ basis from $2.3 million in Q3 2025.
Immucell (ICCC) Accounts Payables (2010 - 2026) Analysis & Trends
Immucell (ICCC) has 16 years of Accounts Payables data on file, last reported at $2.3 million in Q4 2025.
- Quarterly Accounts Payables fell 8.05% year-over-year to $2.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $2.3 million (down 8.05% YoY) and the FY2025 annual result came in at $2.3 million, down 8.05% from the prior year.
- Accounts Payables fell to $2.3 million in Q4 2025, from $2.3 million in the prior quarter.
- In the past five years, Accounts Payables ranged from a high of $2.5 million in Q4 2024 to a low of $6378.0 in Q3 2024.
- A 5-year average of $1.1 million and a median of $1.2 million in 2021 frame the typical range for Accounts Payables.
- Annual changes were most pronounced in 2024 — Accounts Payables sank 99.17% — and 2025, when it soared 36331.64%.
- Tracing ICCC's Accounts Payables over 5 years: stood at $1.6 million in 2021, then grew by 23.95% to $2.0 million in 2022, then advanced by 6.17% to $2.1 million in 2023, then increased by 16.86% to $2.5 million in 2024, then slipped by 8.05% to $2.3 million in 2025.
- The last three Accounts Payables figures came in at $2.3 million (Q4 2025), $2.3 million (Q3 2025), and $884854.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.65 Bn | 130.80 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.93 Bn | 77.94 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.84 Bn | 59.66 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 57.38 Bn | 52.25 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.94 Bn | 36.84 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.54 Bn | 28.23 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 27.72 Bn | 9.33 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.49 Bn | 26.33 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 35.57 Mn |
| 10 | Immucell | 91.37 Mn | 82.51 Mn | 2.44 Mn | 2.81 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.81 Mn |
| Dec 31, 2025 | 2.28 Mn |
| Sep 30, 2025 | 2.32 Mn |
| Jun 30, 2025 | 884,854.00 |
| Dec 31, 2024 | 2.48 Mn |
| Sep 30, 2024 | 6,378.00 |
| Jun 30, 2024 | 250,000.00 |
| Mar 31, 2024 | 225,000.00 |
| Dec 31, 2023 | 2.12 Mn |
| Sep 30, 2023 | 773,026.00 |
| Jun 30, 2023 | 122,096.00 |
| Mar 31, 2023 | 60,640.00 |
| Dec 31, 2022 | 2.00 Mn |
| Sep 30, 2022 | 1.69 Mn |
| Jun 30, 2022 | 33,463.00 |
| Mar 31, 2022 | 1.52 Mn |
| Dec 31, 2021 | 1.61 Mn |
| Sep 30, 2021 | 1.28 Mn |
| Jun 30, 2021 | 1.15 Mn |
| Mar 31, 2021 | 80,213.00 |